LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population

By Natalie GoodridgeNovember 6, 2019October 24th, 2024Healthcare

LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population

https://limflow.com/limflow-announces-positive-six-month-data-from-promise-i-u-s-early-feasibility-study-demonstrating-excellent-amputation-free-survival-and-wound-healing-in-no-option-patient-population/

LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population

LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population

Tags:

PreviousWith eyes on a polumer empire prize, French medtech player seals $42M in fresh funding

NextCagent Vascular Appoints Medical Device Industry Veteran Brian Walsh as Chairman of the Board

M&L GROUP

We are a family investment firm that cultivates pioneering ventures into successful enterprises with passion, energy and integrity.

Hospitality

Healthcare

Shipping

Alternatives

Media room

About

Contact